Oncology | Drugs in Discovery | Pipeline Prospector

Sana Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

What’s it take to raise $700M-plus for a biotech startup? Steve Harr has some thoughts on that

Lead Product(s): Gene and Cell therapies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: RCH Venture Partners

Deal Size: $700.0 million Upfront Cash: Undisclosed

Deal Type: Financing June 23, 2020

Details:

Proceeds from Sana’s financing will be used to advance discovery and development within the company’s core platforms, including gene delivery, immunology, stem cell biology, and gene modification and control.

Almac Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 AACR Virtual Annual Meeting II

Lead Product(s): ADP-c165

Therapeutic Area: Oncology Product Name: ADP-c165

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 18, 2020

Details:

Presentations highlight significant new data for key oncology drug development programmes - USP7 small molecule inhibitors and ROR1 Protein: Drug Conjugates.

Ubiquigent

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Bristol-Myers Squibb

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 17, 2020

Details:

The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb tocapitalise on the strength and breadth of Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise.

Vernalis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 15, 2020

Details:

The new 3 years research collaboration combines Vernalis’ strengths in structure and biophysics-based methods as part of the Vernalis Design Platform with the oncology expertise at Servier to enable to identify and enable new therapeutic targets.

Egle Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda

Lead Product(s): Tumor-infiltrating Treg

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 11, 2020

Details:

Under the terms of the agreement, Egle Therapeutics will lead target validation efforts on a subset targets Egle has identified and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies.

Lycia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Lycia uncloaks with $50M to Tackle Protein Degradation

Lead Product(s): Lysosome targeting chimeras

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Versant Ventures

Deal Size: $50.0 million Upfront Cash: Undisclosed

Deal Type: Financing June 09, 2020

Details:

Proceeds are being used to develop lysosomal targeting chimeras, or LYTACs, as therapeutics for a broad set of currently intractable cell surface targets.

Alvaxa Biosciences

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Sensei Biotherapeutics Completes Acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics Company

Lead Product(s): Nanobodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Sensei Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition May 27, 2020

Details:

Under the terms of the agreement, Sensei will acquire Alvaxa Biosciences and its existing camelid nanobody libraries, expertise in nanobody discovery, as well as its partnership with Hope Farms, LLC, for the generation of future alpacaderived nanobodies.

AbCellera

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform

Lead Product(s): Antibody

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: OrbiMed

Deal Size: $105.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing May 27, 2020

Details:

With the proceeds of the financing, AbCellera will expand its capacity and invest in technologies that complement and extend its proprietary antibody discovery engine.

Repare Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Bristol-Myers Squibb

Deal Size: $3,000.0 million Upfront Cash: $65.0 million

Deal Type: Collaboration May 26, 2020

Details:

Companies will leverage Repare’s proprietary, CRISPR-enabled genome-wide synthetic lethal target discovery platform, SNIPRx®, to jointly identify multiple synthetic lethal precision oncology targets for drug candidates.

SeraNovo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

SeraNovo Enters into a Second License Agreement with Carna Biosciences for Development of Oral Formulation of Carna’s Kinase Inhibitor

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Carna Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 26, 2020

Details:

Under the agreement, the companies will expand their existing collaboration and jointly continue to develop an oral formulation with an increased bioavailability.

Find

Find Novel Oncology Drugs in Discovery

Discovery

Product Type

Companies

Sana Biotechnology

What’s it take to raise $700M-plus for a biotech startup? Steve Harr has some thoughts on that

Almac Group

Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 AACR Virtual Annual Meeting II

Ubiquigent

Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb

Vernalis

Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets

Egle Therapeutics

Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda

Lycia Therapeutics

Lycia uncloaks with $50M to Tackle Protein Degradation

Alvaxa Biosciences

Sensei Biotherapeutics Completes Acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics Company

AbCellera

AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform

Repare Therapeutics

Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb

SeraNovo

SeraNovo Enters into a Second License Agreement with Carna Biosciences for Development of Oral Formulation of Carna’s Kinase Inhibitor